image
Biotech Resources Group (BRG) helps GMP biologics companies make better manufacturing decisions when it matters most—whether you need to Build new capacity, Optimize an existing facility, or Buy capacity from a CDMO partner. Our BRIDGEONE GMP Services ecosystem turns these complex choices into practical next steps, reducing risk and improving execution across your global manufacturing network. GMP IS IN OUR DNA®
BY THE NUMBERS
FOUNDERS' EXPERIENCE: 50+ yr NETWORK'S COLLECTIVE EXPERIENCE: 200+ yr GMP DIVISION FOUNDED: 2011 RECRUITING DIVISION FOUNDED: 2000 PROJECT GEO: 6 CONTINENTS FACILITIES: 20+ MODALITIES: 5+ CDMO/INNOVATOR/HYBRID: ALL A.I. GOVERNANCE: YES
image
HOSTS: 4DS/DP: YesE-BOOKS: 2+PLAYBOOKS: 3SCI JOURNAL PAPERS: 1TRADEMARKS: 3 SERVICE LANES: 3 NETWORK: GLOBAL LANGUAGES: 6
BUILD ✦ OPTIMIZE ✦ BUY
Biologics is entering a decisive decade: capacity is exploding, pipelines are diversifying, and regulators are raising the bar at the exact moment talent and infrastructure are under pressure. ✦ Doing nothing quietly compounds into capacity shortfalls, repeat deviations, and missed launches—“business as usual” has become one of the most expensive strategies in modern biotech. ✦ If you’re here, it’s because you can see that clearly: you’re either building new capacity and wrestling with a high horsepower EPCM partner, trying to squeeze more safe, reliable throughput from an existing site, or navigating the risk and ambiguity of selecting and managing a DS/DP CDMO.
This is exactly where Biotech Resources Group (BRG) lives and works: Helping GMP biologics companies make better manufacturing decisions at the moments that matter most—whether that’s green/brownfield facility and EPCM support, a hidden capacity and dysfunctional Ops Audit, or sponsor-side CDMO selection, award, and governance— the outcome is to turn complex GMP choices into practical next steps instead of costly hesitation.
SERVICE ECOSYSTEM: BRIDGEONE
3 Service Lanes: Build, Optimize, and Buy
✦ ✦ BUILD ✦ ✦ Facility & EPCM Partner Support BRG supports mature, medium-sized GMP biologics companies as they define, select, engage, score, award, and work with a large, high-horsepower design engineering (EPCM) partner. This service is focused on new facility builds, expansions, and post-acquisition site set-up. Since this is an independent lens, you'll have a voice at the table resulting in a project that is better aligned on capacity, process fit, cost, schedule, and long-term operability. PLAYBOOK 1 : Apply here.
✦ ✦ OPTIMIZE ✦ ✦ 20-40% of your Design-Basis Capacity may be Unused/Hidden. BRG has run the plants we now help you fix. We'll find this hidden capacity in weeks, not the 18-36 months CapEx cycle. We help very mature biologics manufacturers pinpoint where their existing facility is losing throughput — across scheduling, contamination, quality systems, automation, staffing, and legacy design — before defaulting to more CAPEX or CDMO spend. PLAYBOOK 2: Apply here.
✦ ✦ BUY ✦ ✦ CDMO Search, Score, Audit, Selection, Award & Sponsor-Side Management. BRG supports small/medium sized biologics companies as they search, RFI, audit, score, award, and manage a CDMO partner. This service cuts across most modalities and is designed to align program needs, requisite expertise, experience, and project governance. The result is a better-fit CDMO relationship with fewer technical, quality, schedule, and partnership surprises. Note: Serves as a capacity hedge for BIOSECURE + Section 232 challenges. PLAYBOOK 3: Apply here.
image
mAb✦Cytokine✦Inclusion-body✦AAV✦LV✦CAR-T✦RLT✦ADC✦Antibiotics
image
BridgeOne Service Lanes (3)
image
PLAYBOOK-1: EPCM SUPPORT
image
PLAYBOOK-2: Uncovering Hidden Capacity
image
PLAYBOOK-3: CDMO Qualify, Award, & PM
WHEN WE CONNECT
image
"Resolving capacity-specific pain-points significantly lowers internal tension, fostering a more collaborative and productive work environment." - Susan & Bob Valdes, Co-Founders
image
Human Expertise. Clear A.I. Boundaries.
At Biotech Resources Group, you engage human expertise—not A.I.-generated reports. Our A.I. Use, Human Authorship & Content Integrity Policy requires qualified, named experts to develop every report’s framework, narrative, analysis, and recommendations. We permit approved A.I. tools only for defined support tasks, with disclosure and human verification, and prohibit entering confidential client information into tools not approved for that data classification. Sources are personally checked, authors remain accountable, and deliverables undergo documented review. For our clients, that means clear boundaries around A.I. use, safeguards for sensitive information, and advice grounded in professional judgment—not automated synthesis. Our A.I. Policy document will be shared only after CDA execution.
image
image
image
Copyright 2026 Biotech Resources Group, LLC +1 617.858.033.two | +1 202.738.338.six GEO: USA, EU, APAC | www.biotech-1.com Robert & Susan Valdes | bobv@biotech-1.com Washington, D.C. Metro Area | Boston Metro Area Build, Optimize, and Buy
image